Treatment Of Newly Diagnosed, High-Grade, Malignant Glioma With Polifeprosan 20 Containing Carmustine Implant (Gliadel Wafer) Using MR Spectroscopy Data As A Primary Indicator Of Therapeutic Response.

Status: Withdrawn prior to enrolment

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 07 Jun 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carmustine polifeprosan 20 wafer (Primary)
Indications Glioblastoma
Focus Therapeutic Use
Acronyms Gliadel-MRS

Most Recent Events

30 May 2019 Status changed from discontinued to withdrawn prior to enrolment.
26 Aug 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
23 Feb 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight